Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D DayGlobeNewsWire • 11/28/23
Legend Biotech highlights Novartis deal worth up to $1.11BN alongside 3Q resultsProactive Investors • 11/20/23
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASHGlobeNewsWire • 11/20/23
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2GlobeNewsWire • 11/09/23
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decadeGlobeNewsWire • 10/31/23
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)GlobeNewsWire • 10/30/23
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidanceGlobeNewsWire • 10/24/23
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane settingGlobeNewsWire • 10/23/23